We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+12.38%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$4.12B
AUM Growth
+$545M
Cap. Flow
+$53M
Cap. Flow %
1.29%
Top 10 Hldgs %
48.24%
Holding
158
New
26
Increased
23
Reduced
71
Closed
24

Top Buys

Rank Stock Value
1
KLRS
Kalaris Therapeutics
KLRS
+$69M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$68.4M
3
BEKE icon
KE Holdings
BEKE
+$43.5M
4
IGMS
IGM Biosciences
IGMS
+$40.8M
5
ITOS
iTeos Therapeutics
ITOS
+$29.4M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$42.9M
2
PYPL icon
PayPal
PYPL
+$34.8M
3
AVTR icon
Avantor
AVTR
+$34M
4
ARGX icon
argenx
ARGX
+$30.2M
5
Z icon
Zillow
Z
+$22.1M

Sector Composition

Rank Sector Weight
1 Healthcare 57.99%
2 Miscellaneous 26.49%
3 Consumer Discretionary 10.25%
4 Technology 2.5%
5 Real Estate 1.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XLE icon
126
CALL
State Street Energy Select Sector SPDR ETF
XLE
$42.4B
$1.5M 0.04%
100,000
– –
ORTX
127
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$1.45M 0.04%
35,150
-1,850
-5% -$95.6K
CTMX icon
128
CytomX Therapeutics
CTMX
$697M
$1.19M 0.03%
178,600
-9,400
-5% -$69.7K
BLU
129
DELISTED
BELLUS Health Inc.
BLU
$1.08M 0.03%
475,000
+331,237
+230% +$939K
IRWD icon
130
Ironwood Pharmaceuticals
IRWD
$689M
$994K 0.02%
110,532
– –
RIGL icon
131
Rigel Pharmaceuticals
RIGL
$847M
$771K 0.02%
32,110
-1,690
-5% -$41.5K
CDTX
132
DELISTED
Cidara Therapeutics
CDTX
$640K 0.02%
11,234
-591
-5% -$41.7K
PASG icon
133
Passage Bio
PASG
$16.1M
$205K 0.01%
782
-10,918
-93% -$3.76M
AAL icon
134
American Airlines Group
AAL
$8.67B
– –
-1,500,000
Closed -$18.8M
AGIO icon
135
Agios Pharmaceuticals
AGIO
$2.01B
– –
-376,000
Closed -$20.1M
AKBA icon
136
Akebia Therapeutics
AKBA
$267M
– –
-574,000
Closed -$7.79M
ALEC icon
137
Alector
ALEC
$239M
– –
-200,000
Closed -$4.89M
ALNY icon
138
CALL
Alnylam Pharmaceuticals
ALNY
$33.5B
– –
-100,000
Closed -$14.8M
ASND icon
139
Ascendis Pharma A/S
ASND
$17.4B
– –
-65,000
Closed -$9.61M
AVTR icon
140
Avantor
AVTR
$10.3B
– –
-2,000,000
Closed -$34M
BNTX icon
141
CALL
BioNTech
BNTX
$24.8B
– –
-150,000
Closed -$10M
BPMC
142
DELISTED
Blueprint Medicines
BPMC
– –
-550,000
Closed -$42.9M
CYRX icon
143
CryoPort
CYRX
$788M
– –
-89,000
Closed -$2.69M
DAL icon
144
CALL
Delta Air Lines
DAL
$52.5B
– –
-1,250,000
Closed -$35.1M
DNTH icon
145
Dianthus Therapeutics
DNTH
$6.02B
– –
-28,125
Closed -$3.38M
HTHT icon
146
Huazhu Hotels Group
HTHT
$13.1B
– –
-175,000
Closed -$6.13M
IDYA icon
147
IDEAYA Biosciences
IDYA
$3.63B
$0 ﹤0.01%
8
-239,296
-100% -$2.96M
MLCO icon
148
CALL
Melco Resorts & Entertainment
MLCO
$1.92B
– –
-500,000
Closed -$7.76M
NKTR icon
149
Nektar Therapeutics
NKTR
$2.34B
– –
-15,933
Closed -$5.54M
PYPL icon
150
PayPal
PYPL
$46.2B
– –
-200,000
Closed -$34.8M
3 4 5
6
7

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q3 2020 Portfolio in Review

As of Q3 2020, Artal Group held 158 positions worth $4.12B, up 15% from $3.57B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Artal Group's Q3 2020 filing shows 26 new, 23 increased, 71 reduced and 24 closed positions. Its largest new stake was Kalaris Therapeutics: 101,016 shares worth $63.9M. The largest sale was Blueprint Medicines, an estimated $42.9M.

By sector, the portfolio is most concentrated in Healthcare at 58% of assets, down from 62% a quarter earlier, followed by Miscellaneous and Consumer Discretionary.

  • Artal Group's largest Q3 2020 buy was Kalaris Therapeutics: 101,016 shares worth $63.9M.
  • Artal Group added most to Agenus in Q3 2020, an estimated $16.1M increase.
  • Artal Group's biggest Q3 2020 reduction was argenx, cutting an estimated $30.2M.
  • Artal Group fully exited Blueprint Medicines in Q3 2020, selling an estimated $42.9M.
  • Artal Group's ten largest holdings make up 48% of its $4.12B portfolio in Q3 2020.
  • Artal Group opened 26 new positions and closed 24 in Q3 2020.
  • Artal Group's portfolio value rose 15% quarter-over-quarter to $4.12B.

Based on Artal Group's 13F filing for Q3 2020, filed 13 Nov 2020.